Search results
Your search for process/pmg6 returned no results
Showing 451 to 465 of 2854 results for process
Showing 451 to 465 of 2854 results for process
In development Reference number: GID-NG10457 Expected publication date: TBC
This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS209Show all sections
Sections for QS209
- Quality statements
- Quality statement 1: Preventing type 2 diabetes
- Quality statement 2: Structured education programme
- Quality statement 3: Continuous glucose monitoring for adults on multiple daily insulin injections who cannot self-monitor using capillary blood glucose monitoring
- Quality statement 4: Continuous glucose monitoring for adults who use insulin and need help monitoring their blood glucose
- Quality statement 5: Treatment with an SGLT-2 inhibitor
- Quality statement 6: 9 key care processes
- Quality statement 7: Assessing the risk of diabetic foot problems on admission to hospital
In development Reference number: GID-NG10445 Expected publication date: TBC
The NICE glossary provides brief definitions and explanations of terms used on the website. The terms describe how NICE works and how its guidance is produced.
How we collect and use your personal information, and your rights under data protection legislation.
Sugemalimab with chemotherapy for untreated advanced non-small-cell lung cancer [ID6758]
In development Reference number: GID-TA12462 Expected publication date: TBC
Bupivacaine–meloxicam for treating postoperative pain [ID2728]
Awaiting development Reference number: GID-TA10716 Expected publication date: TBC
Venous thromboembolism in over 16s : aspirin following orthopaedic surgery (update)
In development Reference number: GID-NG10469 Expected publication date: TBC
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]
Awaiting development Reference number: GID-TA10791 Expected publication date: TBC
This quality standard covers preventing and treating surgical site infections. It covers adults, young people and children having a surgical procedure that involves a cut to the skin in all healthcare settings. It describes high-quality care in priority areas for improvement.
View quality statements for QS49Show all sections
Sections for QS49
- Quality statements
- Quality statement 1: Personal preparation for surgery
- Quality statement 2: Antibiotic prophylaxis
- Quality statement 3: Patient temperature
- Quality statement 4: Intraoperative staff practices
- Quality statement 5: Information and advice on wound care
- Quality statement 6: Treatment of surgical site infection
- Quality statement 7: Surveillance
This quality standard covers reducing the risk of venous thromboembolism (VTE) in people aged 16 and over who are in hospital. It also covers diagnosing and treating VTE in all people aged 18 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS201Show all sections
Sections for QS201
- Quality statements
- Quality statement 1: Timing of pharmacological venous thromboembolism prophylaxis
- Quality statement 2: Venous thromboembolism risk assessment for people with lower limb immobilisation
- Quality statement 3: Proximal leg vein ultrasound scan for a 'likely' deep vein thrombosis Wells score
- Quality statement 4: Venous thromboembolism anticoagulation review
- Quality statement 5: Follow-up for outpatients with low-risk pulmonary embolism
- Update information
- About this quality standard
This quality standard covers preventing bacterial infection in newborn babies, treating pregnant women and pregnant people whose babies are at risk of infection, and treating newborn babies with suspected or confirmed bacterial infection. It includes when to give antibiotics to prevent and treat neonatal bacterial infection and describes high-quality care in priority areas for improvement. This includes early-onset (within 72 hours of birth) and late-onset (between 72 hours and 28 days following birth) neonatal infection.
View quality statements for QS75Show all sections
Sections for QS75
- Quality statements
- Quality statement 1: Intrapartum antibiotics
- Quality statement 2: Assessment for early-onset neonatal infection
- Quality statement 3: Prompt antibiotic treatment for neonatal infection
- Quality statement 4: Reassessing antibiotic treatment for neonatal infection
- Quality statement 5: Information and support for parents and carers
- Update information
- About this quality standard
Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.
Epilepsies in children, young people and adults (extraordinary review)
In development Reference number: GID-NG10378 Expected publication date: TBC
ID6611 Obesity, overweight - semaglutide (including review of TA875)
Awaiting development Reference number: GID-TA11851 Expected publication date: TBC